Rheumatology Advance Access published online on April 10, 2008
Rheumatology, doi:10.1093/rheumatology/ken094
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis
Academic Unit of Musculoskeletal Disease, University of Leeds and Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK.
Correspondence to:
P. Emery, Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. E-mail: p.emery{at}leeds.ac.uk
 |
Abstract |
|---|
Objective. To investigate the long-term response to biological therapies in AS in a real life clinical setting and to quantify non-response and response to ‘switching’ therapies in these cases.
Methods. All patients prescribed TNF-blocking therapies for AS between 1999 and 2006 were studied. Response was evaluated using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and CRP results.
Results. A total of 113 patients (84 males: 29 females, mean age 45 yrs, median disease duration 16 yrs, 87% HLA-B27 positive) were identified. At baseline they had a mean BASDAI of 6.57, BASFI 6.57 and CRP of 31 g/dl. At the end of follow-up, these values had reduced to mean BASDAI of 3.12, BASFI 4.16 and CRP of 7 g/dl. Improvements were sustained for 24 months and beyond with no loss of effect. Only nine patients (8%) suffered side-effects leading to cessation or switching of first-line therapy and non-response occurred in 15 patients (13%) in the long term. Fifteen patients (13%) switched to a second drug and 14 of these (93%) had a significant and sustained response. Outcomes were similar regardless of drug used, duration of disease and HLA-B27 status.
Conclusion. Treatment of active AS with TNF blockers according to the British Society of Rheumatology guidelines leads to a sustained response for over 2 yrs with most patients tolerating the drugs well. The rate of non-response is significantly lower than that seen in RA and nearly all of these patients respond well to a second-line agent.
KEY WORDS: Ankylosing spondylitis, Biologics, TNF blockers, Treatment, Switching, Non-response
Submitted 10 October 2007;
revised version accepted 6 February 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Scholmerich Balancing the risks and benefits of prolonged use of infliximab Gut, April 1, 2009; 58(4): 477 - 478. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Pradeep, A. C. Keat, K. Gaffney, A. Brooksby, J. Leeder, and C. Harris Switching anti-TNF therapy in ankylosing spondylitis Rheumatology, November 1, 2008; 47(11): 1726 - 1727. [Full Text] [PDF]
|
|